New antibody restricts the growth of aggressive and treatment-resistant breast cancers A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists. The King’s College London discovery, published today, could provide new treatment options for some of the most aggressive forms of breast cancer. This may be particularly important for patients whose cancers no longer respond to existing therapies, as well as those with triple-negative breast cancer – a subtype which lacks the receptors which are common drug targets, where treatment choices remain very limited. The team designed an antibody that not only attacks the tumour cells directly, but also harnesses the body’s own immune defences. The first of its kind ‘triple-engineered antibody’, latches onto cancer cells on one end and draws in immune cells on the other. While researchers have been modifying antibodies to boost their ability to activate immune cells, highly effective ones to be used for the treatment of breast cancer are still needed. The Breast Cancer Now Research Unit at King’s College London has been at forefront of this research for more than a decade. The group focuses on studying the patient’s immune system with a view of designing and testing innovative antibodies able to activate the patient’s immune response. In their latest study, laboratory experiments and animal models revealed the modified antibody bound immune cells more strongly compared to current treatments. This activated the immune cells already present in the tumour to attack it, limiting the growth of tumours in triple-negative and treatment-resistant breast cancers. The researchers also found that the modified antibody activated immune cells circulating in the bloodstream, which could boost the body’s overall ability to detect and fight cancer. First author Dr Alicia Chenoweth, from the Faculty of Life Sciences & Medicine at King’s College London, said: “By making a few key changes in the structure of the antibody, we found that it could activate the immune system much more powerfully than an unmodified antibody currently used in breast cancer treatment. “Many of the immune cells in breast tumours are in a ‘suppressed’ state, difficult to activate with unmodified antibodies. We found our triple-engineered antibodies were not only able to activate these immune cells to kill the cancer cells, but shifted these immune cells to a more ‘activated’ state overall.”

SeromYx Systems, inc. a global leader in antibody functional profiling services and Systems Serology, is proud to announce a research collaboration with the lab of Dr. Jason Lohmueller, a synthetic biologist at the University of Pittsburgh, aimed at advancing the development of CAR-T therapies for solid tumors.

Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer. The research, from the group of Professor Sophia Karagiannis at King’s College London, could help to better understand the responses of patients who receive this type of therapy.

Woburn, MA, February 5th, 2025 — SeromYx Systems, Inc., a global leader in high-throughput antibody characterization and Systems Serology services, today announced the retirement of Chief Executive Officer, Mr. Piers Whitehead, a co-founder of the company,...

Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...

Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...

Woburn, MA, September, 25th, 2024 – SeromYx Systems, a leading provider of GCLP Systems Serology and Antibody characterization services, is excited to announce a new immunobiology collaboration to better understand Post-Acute Sequelae of SARS-CoV-2...